Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study

Roviello, Giandomenico; Gambale, Elisabetta; Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Fornarini, Giuseppe; Rebuzzi, Sara Elena; Basso, Umberto; Bimbatti, Davide; Doni, Laura; Nesi, Gabriella; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Pignata, Sandro; Procopio, Giuseppe; Antonuzzo, Lorenzo

doi:10.1002/cam4.4681

Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after progression to nivolumab and cabozantinib in mRCC.

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study / Roviello, Giandomenico; Gambale, Elisabetta; Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Fornarini, Giuseppe; Rebuzzi, Sara Elena; Basso, Umberto; Bimbatti, Davide; Doni, Laura; Nesi, Gabriella; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Pignata, Sandro; Procopio, Giuseppe; Antonuzzo, Lorenzo. - In: CANCER MEDICINE. - ISSN 2045-7634. - STAMPA. - 11:(2022), pp. 3084-3092. [10.1002/cam4.4681]